Compound and method for treatment of movement disorders

Abstract

The disclosed invention generally relates to pharmaceutical compounds and methods for treating and/or preventing diseases and disorders that often manifest in hyper and/or hypokinetic movements symptoms, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids to subjects in need of treatment. The disclosed invention further relates to cannabinoid pharmaceutical compounds where said compound contains at least some non-cannabinoid components.

What claimed is: 
     
         1 . A method of treating and/or preventing diseases and disorders that manifest in hyper and hypokinetic movements symptoms in subjects in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a pharmaceutical composition one or more times in 24 hours, comprising of an extract of a  Cannabis  plant and at least one pharmacologically inactive substance; and
 where said extract contains at least some tetrahydrocannabinol (THC) isomer and at least some cannabidiol (CBD) isomer in the ratio of 1 (THC) and 2 (CBD) by weight; and   where said composition contains at least some non-cannabinoid components consisting essentially of at least one of: terpenes; sterols; triglycerides; alkanes; squalene; tocopherol; carotenoids; chlorophyll; flavonoid; glycosides and alkaloids.   
     
     
         2 . The method of  claim 1 , where said extract contains at least some tetrahydrocannabinol (THC) isomer and at least some cannabidiol (CBD) isomer in the ratio of 0.5 to 1 (THC) and 1.5 to 2 (CBD) by weight. 
     
     
         3 . The method of  claim 1 , where said extract contains at least some tetrahydrocannabinol (THC) isomer and at least some cannabidiol (CBD) isomer in the ratio of 1 to 1.8 (THC) and 2 to 2.5 (CBD) by weight. 
     
     
         4 . The method of  claim 1 , where said composition contains one or more other cannabinoids. 
     
     
         5 . The method of  claim 1 , where said composition is administered in a sustained release, or extended release, or a combined sustained release and extended release fraction dosage form, or in an immediate release dosage form, or a combined sustained release fraction and immediate release fraction dosage form, or a combination thereof. 
     
     
         6 . The method of  claim 1 , where said composition is administered by a route selected from the group consisting of: oral, intranasal, inhalation, parenteral, transdermal, rectal, vaginal, buccal, and sublingual, or combination thereof. 
     
     
         7 . The method of  claim 1 , where said composition is administered in a dosage form selected from the group consisting of: a tablet, a hard gelatin capsule, a soft gelatin capsule, a non-gelatin capsule, an HPMC capsule, an inhalant, an injectable, a transdermal, a buccal, a sublingual, and a rectal or a vaginal suppository. 
     
     
         8 . The method of  claim 1 , where said treatment involves obtaining from the subject at least once in 90 days at least some vital signs parameters. 
     
     
         9 . The method of  claim 1 , where said composition is administered in combination with one or more other medications. 
     
     
         10 . The method of  claim 1 , where said composition is administered for treating and/or preventing chorea, athetosis, dystonia, tremors, tics, myoclonus, stereotypies, dyskinesia, restless legs syndrome, and Periodic Limb Movement Disorder. 
     
     
         11 . The method of  claim 1 , where said composition is administered for treating and/or preventing hyper and hypokinetic movement symptoms associated with at least one of: Huntington's Disease; Wilson's Disease; Sydenham's Chorea; Chorea Gravidarum; Autosomal Dominant Neurogenetic Syndrome; Huntington's Disease-Like Syndrome; Prion Disease; Spinocerebellar Ataxias; Neuroacanthocytosis; Dentatorubral-Pallidoluysian Atrophy; Brain Iron Accumulation Disorders; Friedreich's Ataxia; Mitochondrial Disease; Rett Syndrome; Cerebrovascular Disease; Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections; Levodopa-Induced Dyskinesia, anti-convulsants and anti-psychotics drugs-related symptoms; Systemic Lupus Erythematosus; Antiphospholipid Syndrome; Tourette Syndrome; Thyrotoxicosis; Polycythaemia Rubra Vera; Spongiform Encephalopathies; Coeliac Disease; Parkinson's Disease; metabolic and endocrine diseases and disorders; athetosis-related to damage or degeneration of basal ganglia; minor tranquilizers and alcohol withdrawal syndromes; symptoms or side effects associated with anti-retroviral therapy, chemotherapy and radiation therapy. 
     
     
         12 . The method of  claim 1 , where said tetrahydrocannabinol (THC) or said cannabidiol (CBD) is one or more of: (i) natural cannabinoids that have been purified or modified; (ii) synthetically derived cannabinoids; (iii) semi-synthetic cannabinoids; (iv) esterified cannabinoids; (v) active metabolites of any of the foregoing, (vi) pro-drugs of any of the foregoing; (vii) analogs of any of the foregoing; (viii) derivatives of any of the foregoing; (ix) and mixtures thereof. 
     
     
         13 . The method of  claim 1 , where said composition is a liquid solution or liquid suspension.